Research

Hormonal

Tirzepatide significantly reduces body weight and improves lipid profiles (lowering LDL-C and triglycerides, raising HDL-C) in patients with T2DM and obesity.

Tirzepatide is a once-weekly injection that significantly reduces body weight and improves lipid profiles (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with T2DM and obesity. The benefits are dose-dependent.

StrongSupportsVERY_HIGH confidence
Tirzepatide has also been shown to significantly reduce body weight in clinical trials... Tirzepatide has been shown to improve lipid profiles in clinical studies. In humans, tirzepatide, whether used as monotherapy or add-on therapy, lowered the percentage change of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TGs) and significantly increased high-density lipoprotein cholesterol (HDL-C).
Yun Kyung Cho et al. · Journal of Lipid and Atherosclerosis · 2023

Why this rating

Based on multiple large phase 3 clinical trials (SURPASS, SURMOUNT).

Source

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist

Yun Kyung Cho et al. · Journal of Lipid and Atherosclerosis · 2023

narrative_reviewCited 52×
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →